Shares of CRISPR ... Therapeutics is pursuing the development of CRISPR candidates to create novel CAR-T cell therapies. Management is developing two next-generation CAR-T therapy candidates ...
Zacks.com on MSN14d
CRISPR Therapeutics Stock Falls 34% in a Year: Time to Buy or Sell?Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, thanks to the FDA approval of its one-shot gene therapy Casgevy for two blood ...
Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, thanks to the FDA approval of its one-shot gene therapy Casgevy for two blood ...
Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, thanks to the FDA approval of its one-shot gene therapy Casgevy for two ...
Beyond Casgevy, CRISPR Therapeutics continues to advance its pipeline across multiple therapeutic areas. The company's allogeneic CAR-T cell therapy programs, particularly CTX112 for B-cell ...
Beyond Casgevy, CRISPR Therapeutics continues to advance its pipeline across multiple therapeutic areas. The company's allogeneic CAR-T cell therapy programs, particularly CTX112 for B-cell ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Moreover, Crispr Therapeutics has reported encouraging initial clinical data from its Phase I/II trial of CTX112, an allogeneic CAR-T therapy for CD19-positive B-cell malignancies, highlighting ...
CRISPR Therapeutics' lone approved product has billion ... designation to the company's CTX112, a potential therapy for certain B-cell malignancies. This designation is reserved for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback